Evotec SE, a leading integrated drug discovery and development player, marked a pivotal shift in late 2025 by selling its Just – Evotec Biologics Toulouse manufacturing site to Sandoz, transitioning toward an asset-light model. This move strengthens liquidity and preserves long-term licensing and royalty income, underscoring a new phase emphasizing operational excellence alongside platform innovation across modalities such as small molecules and cell therapies. While revenue growth has moderated with challenges in net profitability driven by elevated R&D investment and restructuring costs, the company’s integrated technology stack and broad partnership ecosystem position it well for selective growth. Key risks remain partner dependency and execution as Evotec balances innovation investments with capital discipline.